Patent ID: 11965875
Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
Field: Measurement (Instruments)
Classification: CPC G | IPC C  G

Claim 0:
1. A method of screening an agent for tumor immunotherapy, comprising assessing the effect of an analyte on tumor immune cells, the method comprises the steps of:
i) assessing the effect of the analyte on target cells, when the target cells are T cells;
ii) assessing the effect of the analyte on non-target cells; and
iii) assessing the effect of the analyte on tumor immune infiltration;
wherein step i) comprises:
i-1) assessing the effect of the analyte on the proliferative capacity of immune cell line target cells, and
i-2) assessing the effect of the analyte on the IL-2 expression level of primary immune cell target cells;
wherein after the assessment of step i-1), the assessment result is divided into two levels of positive (+) and negative (−), and the analyte with a negative assessment result is directly determined as a negative analyte without performing any subsequent steps;
step i-2) is continued for the analyte with a positive assessment result in the step i-1), and the assessment result is divided into two levels of positive (+) or negative (−); the analyte with a negative assessment result in step i-2) is directly determined as a negative analyte without performing any subsequent steps;
step ii) comprises assessing the effect of the analyte on the cell viability of immune cell line non-target cells, and/or assessing the effect of the analyte on the cell viability of primary immune cell non-target cells,

iv) determining the analyte with a level of positive (+) assessment after step i-2) as the agent for tumor immunotherapy.